Journal List > J Korean Diabetes Assoc > v.30(2) > 1062368

TOOLS
Kwon, Rhee, Kim, Kim, Chon, Jung, Yun, Kim, Sung, Kim, Lee, Oh, Kang, Kim, Lee, and Park: The Association of Pro12Ala Polymorphism in PPAR-γ Gene with Coronary Artery Disease in Korean Subjects
Original Article
The Journal of Korean Diabetes Association

The Journal of Korean Diabetes Association 2006; 30(2): 122-129.

Published online: 31 March 2006

DOI: https://doi.org/10.4093/jkda.2006.30.2.122

The Association of Pro12Ala Polymorphism in PPAR-γ Gene with Coronary Artery Disease in Korean Subjects

Chang-Hee Kwon, Eun-Jung Rhee, Se-Yeon Kim1, Eun-Ran Kim, Chang-Uk Chon, Chan-Hee Jung, Ji-Ho Yun, Byung-Jin Kim, Ki-Chul Sung, Bum-Su Kim, Won-Young Lee, Ki-Won Oh, Jin-Ho Kang, Sun-Woo Kim, Man-Ho Lee, Jung-Roe Park

Department of Internal Medicine, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, Korea.

1Institute of Medical Research, Kangbuk Samsung Hospital, Seoul, Korea.

Received 27 October 2005       Accepted 16 January 2006

Copyright © 2006 Korean Diabetes Association

Abstract

Background

PPAR-κ, a member of nuclear family, which is involved in the differentiation of adipose tissue, is reported to be associated in the pathogenesis of type 2 diabetes mellitus, insulin resistance and atherosclerosis. We conducted a research to see whether the prevalence of coronary artery disease is associated with Pro12Ala polymorphism in exon B of PPAR-κ in Korean adults.

Methods

The study was conducted in 161 subjects (97 males, 64 females, mean age 57 year old) who underwent coronary angiogram due to chest pain. We assessed cardiovascular risk factors in all subjects, such as blood pressure, body mass index (BMI), fasting blood sugar and serum lipid profiles. Subjects were divided into four groups as normal, 1-vessel, 2-vessel and 3-vessel disease according to the number of stenosed coronary arteries. Genotypings of Pro12Ala polymorphism were done with Real-time polymerase chain reaction.

Results

Allelic frequency for proline was 0.957 and 0.043 for alanine, and they were in compliance with Hardy-Weinberg equilibrium (P = 0.85). 79 subjects (43.5%) had normal coronary artery, 52 subjects (31%), 1-vessel disease, 24 subjects (14.9%), 2-vessel disease and 15 subjects (9.3%), 3-vessel disease. When the cardiovascular risk factors were compared among these four groups, there were no meaningful differences except the age and high-density lipoprotein cholesterol levels, which were lost after adjustment for age and BMI. There were no significant differences in the prevalence or severity of coronary artery diseases according to the different genotypes of Pro12Ala polymorphism.

Conclusions

There was no significantassociation between Pro12Ala polymorphism in exon B of PPAR-κ and prevalence or severity of coronary artery disease in Korean adults. It is considered that further studies on the correlation between Pro12Ala polymorphism and coronary artery disease should be carried out in larger Korean population in the future.

Keywords: Coronary angiogram, Coronary heart disease, Pro12Ala polymorphism

Figures and Tables

Table 1
The General Characteristics of the Participants
jkda-30-122-i001

Values are presented as mean ± SDs. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Table 2
Differences of the Variables between Different Groups according to the Severity of Coronary Artery Disease
jkda-30-122-i002

Values are presented as mean ± SDs. BMI, body mass index; BP,blood pressure; FBS, fasting blood glucose; T-chol, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.

*The significance was lost after adjustment for age and BMI by ANCOVA test (P = 0.518).

Table 3
Comparison of Cardiovascular Risk Factors according to Different Genotypes of Pro12Ala Polymorphism in Exon B of PPAR-κ Gene
jkda-30-122-i003

Values are presented as mean ± SDs. BMI, body mass index; BP, blood pressure; FBS, fasting blood glucose; T-chol, total cholesterol; TG, triglyceride; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol

*The significance was lost after adjustment for age and BMI by ANCOVA test (P = 0.518)

Table 4
Association of Pro12Ala Polymorphism in Exon B PPAR-κ Gene with Metabolic Syndrome and Diabetes Mellitus
jkda-30-122-i004

All the percentages are calculated within the same genotype groups. Chi-square test was used to compare the frequencies of the diseases according to different genotypes.

Table 5
Association of Pro12Ala Polymorphism in Exon B PPAR-κ Gene with Coronary Artery Disease
jkda-30-122-i005

All the percentages are calculated within the same genotype groups. Chi-square test was used to compare the frequencies of coronary artery disease according to different genotypes.

References

1. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005. 111:3481–3488.
2. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J. 1984. 288:1401–1404.
3. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA. 1994. 272:1666–1671.
4. Peng DQ, Zhao SP, Nie S, Li J. Gene-Gene interaction of PPARr and ApoE affects coronary heart disease risk. Int J Cardiol. 2003. 92:257–263.
5. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura Y, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000. 20:1595–1599.
6. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999. 100:2473–2476.
7. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 1999. 354:141–148.
8. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000. 405:421–424.
9. Desvergne B, Wahli W. Peroxisome proliferators-activated receptors: nuclear control of metabolism. Endocr Rev. 1999. 20:649–688.
10. Rosen ED, Spiegelman BM. PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001. 276:37731–37734.
11. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000. 49:497–505.
12. Marx N, Duez H, Fruchart J-C, Steals B. Peroxisome proliferators-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004. 94:1168–1178.
13. Staels B. PPARgamma and atherosclerosis. Curr Med Res Opin. 2005. 21:Suppl 1. S13–S20.
14. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V. Pro12Ala substitution in the peroxisome proliferators activated receptor-2 is not associated with type 2 diabetes. Diabetes. 1999. 48:1466–1468.
15. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferators activated receptor and diabetes mellitus. Biocheml Biophys Res Commun. 1999. 254:450–453.
16. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, Beamer BA, Charpentier G, Guy-Grand B, Froguel P, Vaisse C. The Pro115Gln and pro12Ala PPAR gene mutations in obesity and type 2 diabetes. Intl J Obes Relat Metab Disord. 2000. 24:391–393.
17. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki T, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biocheml Biophys Res Commun. 2000. 271:212–216.
18. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deep SS, Amouyel P. Impact of the Peroxisome Proliferator Activated Receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord. 2000. 24:195–199.
19. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000. 26:76–80.
20. Memisoglu A, Hu FB, Hankinson SE, Liu S, Meigs JB, Altshuler DM, Hunter DJ, Manson JE. Prospective Study of the Association Between the Proline to Alanine Codon 12 Polymorphism in the PPARgamma Gene and Type 2 Diabetes. Diabetes Care. 2003. 26:2915–2917.
21. Kao WH, Coresh J, Shuldiner AR, Boerwinkle E, Bray MS, Brancati FL. Pro12Ala of the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African Americans: the Atherosclerosis Risk in Communities Study. Diabetes. 2003. 52:1568–1572.
22. Danawati CW, Nagata M, Moriyama H, Hara K, Yasuda H, Nakayama M, Kotani R, Yamada K, Sakata M, Kurohara M, Wiyono P, Asdie H, Sakaue M, Taniguchi H, Yokono K. A possible association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 gene with obesity in native Javanese in Indonesia. Diabetes Metab Res Rev. 2005. 21:465–469.
23. Oh EY, Min KM, Chung JH, Min YK, Lee MS, Kim KW, Lee MK. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab. 2000. 85:1801–1804.
25. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, Zee RY. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003. 23:859–863.
26. Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, Zawadzki C, Haulon S, Kubaszek A, Koehler C, Leonhardt W, Staels B, Laakso M. Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab. 2004. 89:4238–4242.
27. Bluher M, Klemm T, Gerike T, Krankenberg H, Schuler G, Paschke R. Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus. Eur J Endocrinol. 2002. 146:545–551.
28. Pischon T, Pai JK, Manson JE, Hu FB, Rexrode KM, Hunter D, Rimm EB. Peroxisome proliferators-activated receptor gamma2 P12A polymorphism and risk of coronary heart disease in US men and women. Arterioscler Thromb Vasc Biol. 2005. 25:1654–1658.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001. 285:2486–2496.
30. Kim KS, Choi SM, Shin SU, Yang HS, Yoon Y. Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. Metabolism. 2004. 53:1538–1543.
31. Moon MK, Cho YM, Jung HS, Park YJ, Yoon KH, Sung YA, Park BL, Lee HK, Park KS, Shin HD. Genetic polymorphisms in peroxisome proliferator-activated receptor gamma are associated with Type 2 diabetes mellitus and obesity in the Korean population. Diabet Med. 2005. 22:1161–1166.
32. Yamamoto J, Kageyama S, Nemoto M, Sasaki T, Sakurai T, Ishibashi K, Mimura A, Yokota K, Tajima N. PPARgamma2 pro12Ala polymorphism and insulin resistance in Japanese hypertensive patients. Hypertens Res. 2002. 25:25–29.
33. Yamamoto Y, Hirose H, Miyashita K, Nishikai K, Saito I, Taniyama M, Tomita M, Saruta T. PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism. 2002. 51:1407–1409.
34. Puddu P, Puddu GM, Muscari A. Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression? Int J Cardiol. 2003. 90:133–140.
35. Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol. 2003. 92:3J–9J.
36. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet. 1998. 7:435–440.
37. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferators-activated receptor gamma C161T polymorphism and coronary artery disease. Cardiovasc Res. 1999. 44:588–594.
TOOLS
ORCID iDs

Chan-Hee Jung
https://orcid.org/http://orcid.org/0000-0001-8988-0187

Similar articles